A Principled Framework for Optimizing Pharmacovigilance Risk Communication

Thesis Abstract

In the wake of increasing complexity and public scrutiny of pharmacovigilance systems, there is a critical need for a principled framework that optimizes risk communication to diverse stakeholders, including patients, healthcare professionals, and regulatory bodies, to improve interpretation, trust, and reporting behaviors. This study addresses the gap between risk communication theory and practical pharmacovigilance outcomes by developing and validating a comprehensive framework that integrates communication science, health literacy, and risk perception within pharmacovigilance processes. The aim is to design a transferable framework that standardizes risk communication practices while allowing contextual adaptation across regulatory jurisdictions. The specific objectives are (1) to identify determinants of effective pharmacovigilance risk communication across stakeholder groups; (2) to construct a conceptual model linking risk communication strategies to reporting propensity and risk comprehension; (3) to empirically test the model using mixed methods; (4) to quantify the impact of tailored communication interventions on reporting behavior and adverse event comprehension; and (5) to propose a set of actionable guidelines for regulators and pharmaceutical stakeholders. A mixed-methods research design is employed, combining qualitative and quantitative strands to achieve convergent validation. The population comprises pharmacovigilance professionals, community pharmacists, physicians, and adult patients in three metropolitan regions with distinct regulatory environments. Purposive sampling identifies 60 pharmacovigilance experts for in-depth interviews and 600 stakeholders (200 patients, 200 physicians, 200 pharmacists) for surveys. Data collection instruments include semi-structured interview guides informed by the Health Belief Model and Communication Accommodation Theory, a standardized risk literacy questionnaire, and a pharmacovigilance communication effectiveness scale developed for this study. Validity and reliability are established through pilot testing (n=30 for surveys), content validity by an expert panel, Cronbach’s alpha thresholds above 0.70 for scales, and triangulation across data sources. Quantitative data are analyzed using structural equation modeling to test the hypothesized pathways among communication strategies, risk perception, literacy, and reporting intention, complemented by multiple regression analyses to assess intervention effects. The qualitative data undergo thematic analysis guided by Braun and Clarke’s method to extract themes relating to trust, clarity, cultural relevance, and perceived usefulness of information, followed by framework refinement through member-checking with participants. The anticipated findings indicate that risk communication effectiveness is maximized when messages are tailored to audience-specific health literacy levels, cultural contexts, and decision-making needs, with enhanced outcomes in reporting intention and accurate risk interpretation. The model is expected to reveal significant direct effects of clarity, perceived credibility, and relevance on reporting propensity, and indirect effects mediated by risk literacy and trust in regulatory institutions. Experimental interventions that incorporate plain-language summaries, visual risk aids, and culturally adapted messages are projected to yield a measurable increase (10–20 percentage points) in reported adverse events and improved score on risk comprehension scales compared with standard communications. The study also expects regional differences in communication preferences, underscoring the need for adaptable guidelines. Contributions to knowledge include (i) a novel, integrative model of pharmacovigilance risk communication grounded in health communication and risk theory, (ii) empirical evidence on how tailored communication processes influence reporting behaviors and comprehension, (iii) a validated instrument suite for assessing pharmacovigilance communication effectiveness, and (iv) practical, evidence-based guidelines for regulators and industry on designing and evaluating risk communications. The main conclusion is that a principled, audience-centered communication framework substantially improves risk understanding and adverse event reporting, thereby enhancing pharmacovigilance surveillance quality. Recommendations emphasize adopting modular communication templates, investing in health literacy improvements, and embedding iterative evaluation mechanisms within pharmacovigilance programs to maintain relevance amid evolving therapeutic landscapes.